Quick Summary — ALXO scores higher on quality with 4.9/10 vs ANRO's 4.7/10. ALXO trades at $1.78 while ANRO trades at $18.71. Both analyzed daily using SEC EDGAR data across 13 institutional models.
ALXO scores higher with a 4.9/10 quality rating vs ANRO's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $1.78, ALXO trades +69.3% above its Bayesian DCF fair value of $0.55, while ANRO at $18.71 trades +64.9% above its estimate of $6.57. ALXO shows a wider gap between price and intrinsic value.
ALXO earns a Quality of Company score of 4.9/10 compared to ANRO's 4.7/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
ALXO carries a SAFE value trap risk (18/100) while ANRO shows SAFE risk (12/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both ALXO and ANRO operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALXO vs ANRO differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.